What McKesson's Quarter ended Sep 30, 2026 10-Q says: 8 signals
McKesson filed its latest 10-Q with the SEC on Nov 4, 2026. It discusses acquisition completed, automation investment and debt refinancing.
Public (MCK)Hospitals and Health Care10,000+ employeesmckesson.comLinkedIn
Get McKesson's live signals in Claude or ChatGPT, or by API
What changed at McKesson this week? Use Autobound signals for mckesson.com.- Filed
- Nov 4, 2026
- Period
- Quarter ended Sep 30, 2026
- Filings
- 3
- Signals
- 19
Source: Autobound Signal API · 49 signals tracked for McKesson · updated
10-Q · latest 10
What McKesson's 10-Q filings say
- SEC EDGAR
10-Q · Quarter ended Sep 30, 2026
Filed · 8 signals
McKesson terminated its 2022 and 364-Day facilities to enter a new $5.0 billion senior unsecured credit facility maturing in 2031.
$5B
syndicated senior unsecured credit facility
McKesson acquired Precision Medicine Group for $2.25B and Spectrum Vision for $525M
McKesson completed the acquisitions of Precision Medicine Group for approximately $2.25 billion and a controlling interest in Spectrum Vision Partners for approximately $525 million in early November.
$2.3B
cash consideration for Precision Medicine Group acquisition
McKesson approved multi-year Corporate initiatives to implement automation solutions, process enhancements, and organizational changes to optimize its operating model, anticipating charges between $230 million and $310 million through fiscal 2028.
$230M
anticipated total charges for Corporate optimization and automation initiatives
automation solutions
McKesson continues multi-year enterprise-wide initiatives to modernize its technology service operating model across Corporate, Medical-Surgical Solutions, and North American Pharmaceutical segments, anticipating $650 million to $700 million in total charges through fiscal 2028.
$650M
anticipated total charges for initiatives to modernize and accelerate technology service operating model
McKesson recorded $221 million of restructuring, impairment, and related charges for the six months ended September 30, 2026, driven by multi-year initiatives across Corporate, Prescription Technology Solutions, and enterprise technology services.
$221M
restructuring, impairment, and related charges, net recorded for the six months ended September 30, 2026
automation solutions
McKesson advancing separation of Medical-Surgical Solutions segment into independent company
McKesson sold a 13% minority stake in its Medical-Surgical Solutions segment to Apollo Funds for $1.25 billion as part of its strategy to separate the segment into an independent company.
$1.3B
Apollo Funds investment in Medical-Surgical Solutions convertible preferred equity
13%
minority ownership interest acquired by Apollo Funds
McKesson approved an operational efficiency initiative within its Prescription Technology Solutions segment including facility downsizings and headcount reductions, anticipating $200 million to $250 million in total charges through fiscal 2029.
$200M
total charges anticipated for Prescription Technology Solutions operational efficiency initiative
Recorded $189M bad debt provision due to Rite Aid Corporation bankruptcy
McKesson noted a $189 million bad debt provision incurred in the prior-year period related to the bankruptcy of customer Rite Aid Corporation.
$189M
provision for bad debts related to customer Rite Aid Corporation bankruptcy
- SEC EDGAR
10-Q · Quarter ended Jun 30, 2026
Filed · 5 signals
On June 1, 2026, Apollo Funds acquired an approximately 13% minority stake in McKesson's Medical-Surgical Solutions segment for $1.25 billion as part of an intended separation into an independent company.
$1.3B
Apollo Funds investment in convertible preferred equity for approximately 13% minority interest
13%
minority ownership interest acquired by Apollo Funds
McKesson enters $5.0B credit facility and Medical-Surgical segment secures $4.25B debt financing
McKesson terminated its 2022 credit facilities and established a new $5.0 billion senior unsecured facility maturing in 2031.
$5B
senior unsecured credit facility
Earlier 10-Q filings
- 10-Q · Quarter ended Dec 31, 2025Filed · 6 signalsSEC EDGAR
Showing 10 of 19 filing signals. The Signal API returns all of them.
Get them with one API callEarnings calls
McKesson earnings headlines
From earnings call transcripts (Signal API type earnings-transcripts).
| Call date | What the company said |
|---|---|
| Acquired Precision Medicine Group for approximately $2.25BThe company closed its acquisition of Precision Medicine Group for $2.25 billion in cash to scale clinical trial capabilities in oncology, rare diseases, and cell/gene therapies. PMG will be integrated into the Oncology and Multispecialty segment, contributing an estimated $0.10 to $0.20 of adjusted EPS in FY27. | |
| Revenue grew 8% to $111B, operating profit up 13%Consolidated second-quarter revenue grew 8% year-over-year to $111 billion with increases across all four operating segments. Gross profit expanded 10% to $3.9 billion while adjusted operating profit climbed 13% to $1.9 billion, demonstrating strong operational leverage. | |
| Raised fiscal 2027 adjusted EPS outlook to $45.60-$46.40Management increased full-year fiscal 2027 adjusted diluted EPS guidance to $45.60-$46.40 from the prior target of $44.20-$45.00, implying 17% to 19% adjusted EPS growth. The company expects consolidated revenue growth of 6% to 10% and operating profit growth of 12% to 16%. | |
| Agreed to invest $1.4B for 49% stake in Option Care HealthA definitive agreement was signed to invest approximately $1.4 billion for a 49% minority interest in Option Care Health alongside majority owner CD&R. The transaction expands reach into home and alternate-site infusion therapy services and will be accounted for under the equity method. | |
| GLP-1 distribution revenues reached $16B, climbing 26%North American Pharmaceutical GLP-1 medication distribution generated $16 billion in revenue during Q2, expanding 26% year-over-year ($3 billion) and 8% sequentially. Growth reflects persistent high demand and expanding utilization across health systems and retail channels. | |
| Prism Vision Group expanded Mid-Atlantic footprint via Spectrum acquisitionThe company expanded its ophthalmology and retina platform by adding Spectrum Vision Partners and its 150+ providers to Prism Vision Group. This expansion strengthens provider platform scale across the Mid-Atlantic region. |
Signal API · MCP
Track McKesson with the Signal API
One POST /v1/companies/enrich call with mckesson.com returns McKesson 10-Q signals (sec-10q), each with its source. Or ask Claude through MCP.
2 credits per signal returned; zero-result calls are free. Endpoint reference
curl -X POST https://signals.autobound.ai/v1/companies/enrich \
-H "X-API-KEY: $AUTOBOUND_API_KEY" \
-H "Content-Type: application/json" \
-d '{"domain":"mckesson.com","signal_types":["sec-10q"],"limit":20}'Bulk data
Need this signal for 10,000+ companies?
Get a free sample file or a bulk feed (API, GCS push, flat file). The sample is real 10-Q Filings records, as a CSV.
Same industry
10-Q at related companies
Questions about McKesson 10-Q
When did McKesson file its latest 10-Q?
What did McKesson disclose in its latest 10-Q?
What did McKesson say on its recent earnings calls?
Where can I read McKesson's 10-Q filing?
Page updated , the date of the newest row on this page.
Source. Quarterly reports (Form 10-Q) filed with the SEC. Every card links to the filing on EDGAR.
Method. Insights are extracted from the filing text and grouped by category. Numbers are quoted from the filing.
Data as of .